Pregnancy and pregnancy rates in association with isotretinoin (Accutane)

被引：7

作者：

Brinker, A ^{[1
]}

Trontell, A ^{[1
]}

Beitz, J ^{[1
]}

机构：

[1] US FDA, Off Drug Risk Safety, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2002年 / 47卷 / 05期

关键词：

D O I：

10.1067/mjd.2002.124700

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 [皮肤病与性病学];

摘要：

引用

页码：798 / 799

页数：2

共 4 条

[1]

LAFLORE JE, 2000, FDA DERM DRUGS ADV C

[2]

A PREGNANCY-PREVENTION PROGRAM IN WOMEN OF CHILDBEARING AGE RECEIVING ISOTRETINOIN [J].

MITCHELL, AA ;

VANBENNEKOM, CM ;

LOUIK, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (02) :101-106

[3]

MITCHELL AA, 2001, FDA DERM DRUGS ADV C

[4]

Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin [J].

Strauss, JS ;

Leyden, JJ ;

Lucky, AW ;

Lookingbill, DP ;

Drake, LA ;

Hanifin, JM ;

Lowe, NJ ;

Jones, TM ;

Stewart, DM ;

Jarratt, MT ;

Katz, I ;

Pariser, DM ;

Pariser, RJ ;

Tschen, E ;

Chalker, DK ;

Rafal, ES ;

Savin, RP ;

Roth, HL ;

Chang, LK ;

Baginski, DJ ;

Kempers, S ;

McLane, J ;

Hong, J ;

Leach, EE ;

Bryce, G ;

Eberhardt, D .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (02) :196-207

← 1 →